Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug targets, each awaiting further validation, but having… Read More
Protein Biochips - On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. On the surface… Read More
CNS Drug Discovery - Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Despite the huge resources that have… Read More
By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed at restricting the utilisation… Read More
Proteomatics - New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Somewhat more prosaically, industrial bioinformatics… Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and to use… Read More
By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More
Drug development for skin diseases based on functional genomics By Dr Jorn-Peter Halle With the high number of sufferers from skin disease around the world, it is astonishing that there are relatively few treatments available and that many of these only serve to relieve symptoms. Can drug development based on… Read More
Fine-tuning the technology strategies for lead finding By Sandra Fox, Dr Shauna Farr-Jones, Dr Lynne Sopchak and Dr Helen Wang HTS has become the workhorse of pharmaceutical and biotechnology companies' drug discovery efforts, with expanding responsibilities and increasing pressures to screen more targets with better compound libraries to find high-quality… Read More
Monoclonal Antibodies - Magic bullets or a shot in the dark By Dr Fiona Adair It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in phase III… Read More
Nanolitre Dispensing - On the point of delivery By Dr John Comley Precise low-volume liquid handling methodologies are still sought after by those interested in enabling miniaturised HTS. This article reviews the need for nanolitre dispensing and provides a current perspective on those emerging technologies that have the potential to… Read More
Biotechnology, Bioterrorism & Biosecurity By Dr George Poste Advances in genetics and biotechnology offer great promise in the fight against infectious diseases. But the same technologies will also increase the threat from bioterrorism. Governments must accord 'biosecurity' a higher priority in defence and foreign policies to reduce the risk of… Read More
High throughput genomics and drug discovery - parallel universes or a continuum? By Dr Mark Beggs and Audrey Long HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a 'high throughput' mode for approximately four years for… Read More
Lead Generation and Lead Optimisation: the value of linking HT co-structure analysis and HT chemistry By Dr David U Prichard The coupling of High Throughput co-structure analysis with focused library generation is not only proving a powerful general tool in lead optimisation but also increasing the probability of successful discovery… Read More
By Dr Mark L. Nelson Less than a hundred years ago, if you developed a microbial infection your immune system couldnt handle, you died. Then came the wonder drugs, antibiotics capable of fighting the infections for you. But times have changed. Now, because of antibiotics, their use and misuse, the… Read More
The Future of Cardiovascular Gene Therapy By Christopher J. Reinhard Advances in regenerative medicine go hand in hand with new perspectives and insights into potential treatments for heart disease. After a decade of pre-clinical and early Phase 1 and 2 clinical studies, gene therapy is now emerging as a genuine… Read More